# BKPyV—Co-Architect of the Fate of a Renal Transplant During a One-Year Observation Period

**Authors:** Jacek Furmaga, Marek Kowalczyk, Olga Furmaga-Rokou, Christos A. Rokos, Tomasz Zapolski, Agnieszka Styczeń, Anna Iwan, Dominika Matera, Beata Ewa Chrapko, Leszek Krakowski, Andrzej Jakubczak

PMC · DOI: 10.3390/ijms27062832 · 2026-03-20

## TL;DR

This study tracks BKPyV in kidney transplant recipients over a year, showing that detecting BKPyV in urine early is more important for predicting complications than later blood-based detection.

## Contribution

The study identifies DNAuria-BKPyV as a more sensitive and earlier predictive marker than BKPyV-DNAemia for post-transplant complications.

## Key findings

- Genotype I was predominant after renal transplantation, with DNAuria-BKPyV peaking at three months.
- DNAuria-BKPyV was detected in more patients and had higher viral loads than BKPyV-DNAemia.
- Early detection of DNAuria-BKPyV is suggested as a key marker for clinical monitoring and intervention.

## Abstract

To identify BKPyV, the VP1 protein sequence was analyzed and classified into genotypes in 246 RTRs before and after RTx from deceased donors during a one-year observation period. Quantitative assessment of BKPyV was conducted via qPCR. Prior to RTx, genotypes I and IV were identified in the urine (7.27 × 106; 1.20 × 105) and in serum (5.75 × 104; 1.12 × 104). After RTx, genotype I was predominant; identification of DNAuria-BKPyV (62.07%) and BKPyV-DNAemia (55.56%) peaked after three months, and the highest DNAuria-BKPyV titer was also observed after three months (6.48 × 109), whereas the BKPyV-DNAemia titer did not peak until after six months (2.21 × 107). The highest number of copies of genotype IV in the urine was observed after six months (9.54 × 109), while the highest titer in the serum was not observed until after 12 months (3.88 × 106). DNAuria-BKPyV precedes BKPyV-DNAemia, affects a larger group of patients, and has a greater and more easily detected viral load, which makes it not only an earlier marker, but the key predictive marker of greater clinical value than later detection of BKPyV-DNAemia alone. Early monitoring of DNAuria-BKPyV should be the basis of classical screening, and not merely an addition to it, and therapeutic interventions should be undertaken early to prevent nephropathy.

## Linked entities

- **Proteins:** VP1 (pyrophosphate-energized vacuolar membrane proton pump 1)

## Full-text entities

- **Diseases:** nephropathy (MESH:D007674)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13027097/full.md

---
Source: https://tomesphere.com/paper/PMC13027097